Clinical analysis of 82 cases of carcinoma showing thymus-like differentiation of the thyroid

Abstract

The aim of the present study was to summarize the clinical characteristics, diagnosis, treatment and prognosis of carcinoma showing thymus-like differentiation of the thyroid (CASTLE). A search of the relevant literature was conducted, which identified 82 cases of CASTLE reported to date. A review of the clinical and auxiliary examination data, treatment, pathological findings and follow-up of these cases was performed. The clinical manifestations of CASTLE varied and did not demonstrate specificity. During ultrasound examination, CASTLE was described as a solid and hypoechoic mass, and the echo was typically observed to be heterogeneous. In computed tomography (CT), CASTLE was demonstrated to be a well-defined, soft tissue density mass without calcification, which appeared enhanced following administration of contrast medium. In emission CT, CASTLE was revealed as a ‘cold nodule’. A total of 78 patients underwent radical surgery, and 12 patients experienced recurrence. Lymph node metastasis did not promote recurrence, and postoperative radiation was not able to reduce the recurrence rate (P=0.144 and 1.000, respectively). The median follow-up time was 14 months (range, 1–312 months). Typical immunohistochemical examinations demonstrated the specimens to be positive for cluster of differentiation (CD)5, CD117, cytokeratin 19, epithelial membrane antigen and tumor protein 63, and negative for calcitonin, thyroglobulin and thyroid transcription factor-1. Thyroid CASTLE is a rare malignancy whose exact diagnosis relies on pathological examination, particularly immunohistochemistry, since preoperative examinations are usually unable to provide an exact diagnosis. Radical resection is the primary treatment for CASTLE, which presents favorable prognosis.

Introduction

Carcinoma showing thymus-like differentiation of the thyroid (CASTLE) is a rare intrathyroidal neoplasm, which may arise from ectopic thymus tissue or branchial pouch remnants (1). Chan and Rosai (2) classified the clinicopathological features of CASTLE into four types: i) Ectopic hamartomatous thymoma; ii) ectopic cervical thymoma; iii) spindle epithelial tumor with thymic-like differentiation; iv) and CASTLE. At present, CASTLE is considered an independent clinicopathological entity of thyroid tumors, according to the World Health Organization classification of tumors of endocrine organs (3). To the best of our knowledge, solely 3 patients have presented with CASTLE at Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School; Nanjing, China) to date. Due to the rarity of CASTLE, there is currently no unified standard method of diagnosis or therapy (1). In 2013, Huang et al (4) summarized 45 cases of CASTLE identified in China. To fully understand this disease, a search of the relevant literature in Pubmed and Chinese databases was performed in the present study, which identified a total of 82 cases of CASTLE reported to date. These cases are summarized in the present study, and recommendations for the diagnosis and treatment of CASTLE are suggested.

Materials and methods

Database search

Electronic searches of the PubMed (www.ncbi.nlm.nih.gov/pubmed), China National Knowledge Infrastructure (www.global.cnki.net/kns50/single_index.aspx) and Ten Thousand databases (http://g.wanfangdata.com.cn) were performed using the following key words: Thyroid, thymus and carcinoma. A total of 82 patients with CASTLE were identified, and their clinical characteristics, diagnosis, treatment, pathology and follow-up were reviewed.

Review of preoperative examinations

The results of preoperative examinations, including ultrasound (n=57), computed tomography (CT; n=27), emission CT (ECT; n=10), thyroid function (n=52) and fine-needle aspiration cytology (n=24), were reviewed. Histopathological examination of surgical specimens was performed using standard hematoxylin and eosin staining (H&E), alongside specific immunohistochemical techniques. The primary immunohistochemical markers were cluster of differentiation (CD)5, CD117, cytokeratin (CK), CK19, CK AE1/AE3, tumor protein (TP)63, carcinoembryonic antigen (CEA), synaptophysin, B-cell lymphoma 2, epithelial membrane antigen (EMA), chromogranin A, calcitonin (CT), thyroglobulin (TG) and thyroid transcription factor-1 (TTF-1). All images are of a single patient and are representative of all patients analyzed.

Statistical analysis

The χ² test was used to evaluate the effects of lymph node metastasis and radiotherapy on recurrence. P<0.05 was considered to indicate a statistically significant difference. All P-values were two-sided. All statistical calculations were performed using SPSS software version 19.0 (IBM SPSS, Armonk, NY, USA).

Results

Baseline characteristics demonstrated wide variations

Of the 82 cases reviewed in the present study, 59 patients were Chinese, 11 were Japanese, 9 were American, 1 was Italian, 1 was Korean and 1 was Portuguese. A total of 37 patients were males and 45 were females. The male:female ratio was 1:1.22. The average patient age was 48.8±12.8 years (range, 25–79 years). The patients presented with a range of symptoms, including a neck tumor in 40 cases (48.78%), hoarseness in 13 patients (15.85%), dyspnea in 8 patients (9.76%), cough in 3 patients (3.66%), neck pain in 3 patients (3.66%) and dysphagia in 1 patient (1.22%). For 14 patients (17.07%), the symptoms were unknown. A total of 34 CASTLE tumors were located in the left lobe of the thyroid, 44 were in the right lobe and 3 were bilateral. In 1 patient, the location of the tumor was unknown. The location of the tumor was more specifically described in 50 cases, of which, 47 presented the tumor in the lower part of the thyroid and 3 in the upper part. The baseline characteristics of the patients are summarized in Table I.

Table I.

Clinical characteristics of 82 patients with carcinoma showing thymus-like differentiation of the thyroid.

Parameter	Number of patients	Percentage
Country
China	59	71.95
Japan	11	13.41
America	9	10.98
Italy	1	1.22
Korea	1	1.22
Portugal	1	1.22
Age, years
<40	23	28.05
40–60	40	48.78
>60	19	23.17
Gender
Male	37	45.12
Female	45	54.88
Symptom
Neck tumor	40	48.78
Hoarseness	13	15.85
Dyspnea	8	9.76
Cough	3	3.66
Neck pain	3	3.66
Dysphagia	1	1.22
Unknown	14	17.07
Thyroid location
Left lobe	34	41.46
Right lobe	44	53.66
Bilateral lobe	3	3.66
Unknown	1	1.22

Preoperative examinations varied from patient to patient

In the present study, descriptions of ultrasound examination were recorded for 57 patients, whose CASTLE was typically described as a solid and hypoechoic mass with heterogeneous echo (Fig. 1). Results of ECT in 10 patients were acquired in the present study, and all tumors were described as ‘cold nodule’. CT examination in 27 patients revealed that CASTLE was a well-defined, soft tissue density mass without calcification, and the mass appeared enhanced following administration of contrast medium. A total of 52 patients underwent a test of thyroid function. Of these, 51 cases were normal and 1 exhibited hyperthyroidism. A total of 24 patients underwent fine-needle aspiration cytology. Of these, 2 patients were diagnosed with CASTLE, 17 cases were demonstrated to be malignant tumors, 1 case was hyperplasia and the remaining 4 cases were negative.

Figure 1.

Ultrasound revealed a mass of 3.8×2.7 cm located in the right lobe of the thyroid. The border between the tumor and the thyroid gland, and between the tumor and the surrounding fat, was irregular. The tumor was solid and displayed a heterogeneous hypoechoic pattern.

Treatment and follow-up demonstrated wide variations across patients

Of the 81 patients who had undergone surgery, lymph node metastasis was observed in 22 patients, and distant metastasis to the lung was identified in 2 patients. Postoperative radiation was administered as an adjuvant therapy in 29 patients, while 4 patients received chemotherapy in addition to radiation. The median follow-up time was 14 months (range, 1–312 months), and no follow-up period was reported for 15 patients. Of the 78 patients who had undergone radical surgery, 12 experienced recurrence, with a median time to recurrence of 11 months (range, 1–144 months; Table II). The effect of lymph node metastasis and radiotherapy on recurrence was subsequently evaluated by χ² test using SPSS software version 19.0 (Table III).

Table II.

Follow-up of 12 patients exhibiting carcinoma showing thymus-like differentiation of the thyroid who experienced recurrence.

Authors	Time until recurrencea, months	Treatment	Follow-up timea, months	Outcome
Liu et al (6)	144	Surgery	27	NED
Liu et al (6)	22	Surgery	44	NED
Bai et al (7)	22	Surgery and radiotherapy	50	NED
Pan et al (8)	3	Surgery, radiotherapy and chemotherapy	12	NED
Luo et al (9)	24	Surgery, radiotherapy and chemotherapy	6	NED
Wu et al (10)	1	Radiotherapy	25	NED
Da et al (11)	6	Surgery	108	NED
Da et al (11)	6	Surgery	132	NED
Da et al (11)	3	Unknown	36	SD
Reimann et al (13)	72	Radiotherapy	96	SD
Reimann et al (13)	36	Surgery	96	NED
Tsutsui et al (12)	16	Surgery	34	NED

^aFollowing surgery. ^bFollowing treatment. NED, no evidence of disease; SD, succumbed to disease.

Table III.

Effect of lymph node metastasis and radiotherapy on recurrence.

Parameter	Recurrence	No recurrence	χ2 value	P-value
Lymph node metastasis			1.482	0.144
Present	6	13
Absent	3	22
Radiotherapy			0.000	1.000
Present	4	25
Absent	3	16

Pathological and immunohistochemical examinations confirmed positivity for certain markers

Microscopic examination revealed the presence of confluent nests and lobules of various glands with a few lymphocytes and plasma cell infiltration (Fig. 2). The immunohistochemical results are summarized in Table IV. Typical immunohistochemical examinations demonstrated positivity for CD5, CD117, CK19, EMA and TP63, and negativity for CT, TG and TTF-1 (Fig. 3).

Figure 2.

Microscopic examination revealed confluent nests and lobules of various glands with a few lymphocytes and plasma cell infiltration. (A) Hematoxylin and eosin staining; magnification, (A) ×40 and (B) ×200.

Table IV.

Immunohistochemical results of 82 cases of carcinoma showing thymus-like differentiation of the thyroid.

Immunological marker	Number of cases studied	Number of positive cases	Percentage
CD5	63	63	100.00
CK	19	10	52.63
CD117	37	36	97.30
CK19	14	14	100.00
Tumor protein 63	32	32	100.00
Carcinoembryonic antigen	25	16	64.00
Synaptophysin	19	5	26.32
CK AE1/AE3	11	11	100.00
B-cell lymphoma 2	14	14	100.00
Epithelial membrane antigen	7	5	71.43
Chromogranin A	9	2	22.22
Thyroglobulin	55	0	0.00
Calcitonin	35	0	0.00
Thyroid transcription factor-1	51	0	0.00

CD, cluster of differentiation; CK, cytokeratin.

Figure 3.

Immunohistochemical examination demonstrated the specimens to be positive for (A) CD5, (B) CD117, (C) cytokeratin 19, (D) epithelial membrane antigen and (E) tumor protein 63, and negative for (F) calcitonin, (G) thyroglobulin and (H) thyroid transcription factor-1. CD, cluster of differentiation.

Discussion

CASTLE is a rare, indolent and slow-growing malignant neoplasm of the thyroid gland, which was initially reported by Miyauchi et al in 1985 (5). According to the relevant literature, and to the best of our knowledge, 82 cases of CASTLE have been reported thus far, primarily in the form of case reports. The present study summarized the clinical characteristics of all the cases of CASTLE published to date in the relevant literature. The male:female ratio was 1:1.22, and the average patient age was 48.8±12.8 years (range, 25–79 years). The clinical manifestations of CASTLE varied across the patients, and were not specific. The majority of previous reports have described CASTLE tumors involving predominantly the lower part of the thyroid, which may be due to CASTLE originating from ectopic thymic tissue or branchial pouch remnants in or adjacent to the thyroid (2,14).

The preoperative diagnosis of thyroid tumors relies on ultrasound, ECT, CT, thyroid function and fine-needle aspiration cytology (1,6–11). In the present study, ultrasound imaging of CASTLE identified a solid and hypoechoic mass, whose echo was typically heterogeneous. Yamamoto et al (15) studied the sonographic findings in three cases of CASTLE and concluded that CASTLE was solid and hypoechoic, with a heterogeneous echo pattern and without cystic components or calcifications, which is in agreement with the results of the present study. CASTLE was previously described as ‘cold nodule’ in ECT, suggesting that it was a malignancy (1). In CT, CASTLE was revealed as a well-defined, soft tissue density mass without calcification, and the mass appeared enhanced following administration of contrast medium (16,17). Tests of thyroid function were normal in almost all the CASTLE cases analyzed, suggesting that CASTLE did not affect the thyroid function (1). A total of 24 patients underwent fine-needle aspiration cytology. Of these, 2 were diagnosed with CASTLE, thus indicating that fine-needle aspiration cytology contributed to the primary diagnosis of CASTLE, while its exact diagnosis depended on pathological and immunohistochemical examination. However, due to the false-negative rates exhibited by fine-needle aspiration cytology, the results should be interpreted with caution, and the examination repeated if required (18).

The preoperative diagnosis of CASTLE is difficult, and conclusive diagnosis often relies on pathological examination, particularly immunohistochemistry (1). A number of studies have indicated that CD5 may be a useful marker for the diagnosis of CASTLE, as it is a marker for carcinoma of thymic origin (19,20). Similar to thymic carcinoma, CASTLE is immunohistochemically positive for CD5, but negative for CT, TG and TTF-1 (19). Ito et al (21) reported a sensitivity and specificity of 82 and 100%, respectively, for CD5 positivity for the diagnosis of CASTLE. In the present study, 63 patients underwent CD5 testing and all demonstrated positivity for this marker, while all the cases tested demonstrated negativity for CT, TG and TTF-1. However, since a lack of CD5 expression does not completely rule out CASTLE, the final diagnosis was based on H&E findings. A previous study reported that expression of high molecular weight CK, CEA and TP63 in CASTLE provided evidence of the thymic origin of the tumor, and were useful diagnostic markers for distinguishing thyroid CASTLE from other thyroid neoplasms (13). In the present study, the positive rates for CK19, CEA and TP63 were 100.00, 64.00 and 100.00%, respectively. Reimann et al (13) reported that the majority of nuclei stained positively for TP63 in 11/11 thyroid solid cell nests, 7/7 CASTLEs, 10/10 thymic carcinomas and 23/23 thymomas. In the present study, TP63 was examined in 32 patients and all cases proved to be positive. In addition, CD117 may be a useful maker for distinguishing CASTLE from other thyroid tumors, since the results of the present study demonstrated a positive rate for CD117 expression of 97.30%.

In the present study, 81 patients underwent surgery. Lymph node metastasis was observed in 22 patients, however, only 19 patients with lymph node metastasis completed follow-up. Postoperative radiation was administered as an adjuvant therapy to 28 patients, and 4 patients received chemotherapy in addition to radiation. Of the 78 patients who had undergone radical surgery, 12 experienced recurrence. The present study evaluated the effects of lymph node metastasis and radiotherapy on recurrence. The results demonstrated that lymph node metastasis did not promote recurrence following radical surgery (P=0.144), and postoperative radiation was not able to reduce the recurrence rate (P=1.000). By contrast, Roka et al (22) reported that node-negative CASTLE presented a low risk of recurrence, and that curative surgery of the tumor with resection of the adjacent organs involved in addition to systematic dissection of the lymph nodes, followed by radiation therapy, was able to prevent locoregional recurrence. Therefore, the findings of the present study require further confirmation, due to the limited sample size of the study.

The prognosis of CASTLE is relatively positive (12). In the present study, the recurrence rate was 18.57% (13/70 patients). During follow-up, 4 patients were reported to succumb to disease, and the longest follow-up time of these 4 patients was 26 years.

In conclusion, thyroid CASTLE is a rare malignancy of the thyroid gland that may display various manifestations. Preoperative examinations, including CT, ECT and ultrasound, may not be capable of establishing an exact diagnosis, which typically requires pathological examination, particularly immunohistochemical results. Radical resection is the primary treatment for CASTLE, and the prognosis for this disease is favorable following surgery. Postoperative radiation appears to be unable to reduce the recurrence rate in patients with CASTLE.